Victorian university courses with the biggest drop out rates
Victorian university students are accumulating debt for degrees they never complete, with new figures revealing one in three fail to graduate.
A Sunday Herald Sun analysis of the latest national Department of Education university completion rate data for domestic students has revealed the courses students are dropping at substantial rates, leaving a portion burdened with HECS-HELP loans and no qualification.
Social work and tourism and hospitality students were among the worst offenders, with more than half the cohort dropping out of their degree between 2018 and 2023.
Despite incentives, education degrees had the third-lowest completion rate, with two in five students dropping out.
Other courses which saw more than 40 per cent of students withdraw included computing and information technology, psychology, and humanities.
Conversely, medicine degrees had the highest completion rate with only one in 10 students dropping out, followed by dentistry, rehabilitation and pharmacy.
Monash University higher education expert Professor Andrew Norton said the two biggest risk factors which could lead to drop outs were weaker academic preparation and part-time study.
'In the period when the 2018 commencers were studying, we have seen increasing rates of part-time study for continuing students, more students working, and the students who are working spending more time at work,' he said.
'I think this is likely to be a key reason why we've seen some worsening attrition rates in recent years (and) is reasonably consistent with the subjective reasons given such as stress, financial difficulties, study workload or employment.'
While it's not known how much money today's students lose when dropping out due to a lack of specific data, Professor Norton said the latest Grattan Institute research on the issue found most students who didn't complete their course would pay or borrow less than $10,000.
'We found most people who dropped out had modest debts but there were some with more significant debts,' he said.
He added a significant portion of dropouts occurred in the first year, resulting in lower debt burdens for those students.
As for the overall completion rate for each Victorian tertiary institution, the University of Melbourne had the highest completion rate with 89.4 per cent of students who started a course in 2018 graduating within six years.
Deputy Vice-Chancellor (Academic) Professor Gregor Kennedy said the institution provides 'extensive academic, enrichment and wellbeing support to students'.
'The University of Melbourne has a strong focus on student connection, belonging and wellbeing, and all students have access to a wide range of activities to supplement their studies,' he said.
Meanwhile, Swinburne University of Technology had the highest drop out rate with 53.8 per cent of students not completing their course.
A Swinburne University of Technology spokeswoman said the institution 'absolutely recognised the need to find new and innovative ways' to support its students' individual needs.
'For some, that is the 'traditional' university experience of a three-year degree. For others, it is studying part time, over an extended period, while they continue working full-time and balancing the demands of life,' she said.
Swinburne University has launched its Education Innovation Exchange which is supporting its first-year refresh project, that works in partnership with schools to address retention and attrition challenges.
Overall, Professor Norton said universities have improved their focus on struggling students and sometimes factors driving attrition rates – such as competing demands on students' time – were out of an institution's control.
'We should also accept that attrition is not always bad if students change their interests or get a job that suits them,' he said. Victorian Unis fork out big cash for WorkCover claims in 2024
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Age
a day ago
- The Age
Ozempic in a pill? The next generation of weight-loss drugs emerges
'The development of GLP-1 and incretin-based drugs has revolutionised the space. It has carved out the biggest class of drugs ever. And it has the power to truly revolutionise our health-span,' said Associate Professor Garron Dodd, head of the Metabolic Neuroscience Research Laboratory at the University of Melbourne and founder of Gallant Bio, which is developing its own obesity drugs. 'It's a glorious dawn, but it's just the start.' Weight loss in a pill Much as our eyes and ears sense the world and send data to our brains, our digestive tracts need ways of sending back data on what they are eating, and how much. They do this, in part, by secreting various chemical signals – hormones. Glucagon-like peptide-1 is secreted by the intestines and triggers the pancreas to produce insulin. The first GLP-1 drugs took advantage of this to become powerful treatments for diabetes. But GLP-1 has much wider effects beyond blood-sugar control. Receptors for the hormone spread throughout the body, even in the brain, where they trigger a feeling of fullness and decrease appetite. A once-weekly dose of semaglutide, plus lifestyle changes, led volunteers in a phase 3 trial to lose 14.9 per cent of their body weight over 15 months. GLP-1 drugs like Wegovy essentially copy that human hormone. That makes them fragile. They need to be kept refrigerated, and injected subcutaneously rather than taken by mouth – as the stomach's acid would quickly break them down. An oral version of semaglutide has been developed, but only 1 per cent of the drug actually makes its way to the target receptors, and it appears less effective than the injectable version for weight loss. Loading Researchers at Japan's Chugai Pharmaceutical Co figured out a way around this problem. They designed a small molecule that can bind to the same receptor as GLP-1 and trigger it. It mimics the effect without mimicking the structure. 'It's a development I never would have thought feasible,' said Professor Michael Horowitz, a University of Adelaide researcher who authored a commentary on the drug in the Lancet. Chugai licensed the molecule to US-based Eli Lilly in 2018. Last week, the company reported participants on the highest dose in a clinical trial lost 7.9 per cent of their body weight over 40 weeks. The full details of the trial have not yet been reported, and whether the weight loss is maintained over the longer term is unclear. More than a quarter of patients reported diarrhoea, 16 per cent nausea and 14 per cent vomiting. The preliminary results are 'close enough to broadly call it similar' to semaglutide, said Professor Jonathan Shaw, who led the Australian arm of Lilly's trial at the Baker Heart and Diabetes Institute in Melbourne. 'I don't think we can confidently say it's better or worse. It's definitely in the same ballpark.' It's also not known if the drug will offer the range of other benefits that GLP-1 inhibitors provide in addition to weight loss, like reductions in cardiovascular disease and Alzheimer's risk (and maybe even addictive behaviours). Horowitz said the efficacy data was promising, but he wanted to see more information about adverse effects, which he said were understated generally across semaglutide trials because they relied on patients to report their own side effects. 'It hasn't served the interests of pharma to quantify how well this is tolerated.' Pfizer was developing a similar once-daily GLP-1 pill but cancelled the program in April after a patient in a clinical trial suffered liver damage. A pill should, theoretically, be cheaper and easier to make than an injector – Novo Nordisk, maker of Wegovy and its diabetes drug antecedent Ozempic, has struggled to keep up with demand for semaglutide – and dramatically easier to transport. At present, the drug must be kept refrigerated right from European factories to a patient's home. 'That all adds to the cost,' said Shaw. There could also be cost benefits from increased competition as more drugs are approved – possibly pushing the price down far enough for governments to consider subsidising it. Lilly expects to apply for regulatory approval for the drug later this year. While orforglipron has attracted the most excitement – Eli Lilly's shares have surged since they announced the trial results – it is just one of several new drugs in late-stage development. These drugs might be of particular value to 15 per cent or so of people whose bodies do not seem to respond to semaglutide. And people don't seem to stay on the injectable drugs – less than half are still using them a year later, per a study 2024 study – despite the fact weight rebound is likely if you stop using them. 'Is it the injection? Is it the cost? Or is it due to adverse effects? We don't know,' said Horowitz. The new drugs might also offer weight-loss benefits. Mounjaro, for example, mimics both GLP-1 and the gastric inhibitory polypeptide, which increases metabolism and appears to lead to better weight-loss results. The new drugs, like Lilly's retatrutide, target even more receptors, with the hope of even greater effects. It's all good news for Rochelle McDonald. She does not mind taking a weekly injection – 'the stabby-stab' – now she's found ways of coping with the side effects. But paying $240 a month for her current dose of the medicine is 'a commitment in itself'. 'I think a daily pill would be good,' she said. 'If it comes in at a good price point.'
Sydney Morning Herald
a day ago
- Sydney Morning Herald
Ozempic in a pill? The next generation of weight-loss drugs emerges
'The development of GLP-1 and incretin-based drugs has revolutionised the space. It has carved out the biggest class of drugs ever. And it has the power to truly revolutionise our health-span,' said Associate Professor Garron Dodd, head of the Metabolic Neuroscience Research Laboratory at the University of Melbourne and founder of Gallant Bio, which is developing its own obesity drugs. 'It's a glorious dawn, but it's just the start.' Weight loss in a pill Much as our eyes and ears sense the world and send data to our brains, our digestive tracts need ways of sending back data on what they are eating, and how much. They do this, in part, by secreting various chemical signals – hormones. Glucagon-like peptide-1 is secreted by the intestines and triggers the pancreas to produce insulin. The first GLP-1 drugs took advantage of this to become powerful treatments for diabetes. But GLP-1 has much wider effects beyond blood-sugar control. Receptors for the hormone spread throughout the body, even in the brain, where they trigger a feeling of fullness and decrease appetite. A once-weekly dose of semaglutide, plus lifestyle changes, led volunteers in a phase 3 trial to lose 14.9 per cent of their body weight over 15 months. GLP-1 drugs like Wegovy essentially copy that human hormone. That makes them fragile. They need to be kept refrigerated, and injected subcutaneously rather than taken by mouth – as the stomach's acid would quickly break them down. An oral version of semaglutide has been developed, but only 1 per cent of the drug actually makes its way to the target receptors, and it appears less effective than the injectable version for weight loss. Loading Researchers at Japan's Chugai Pharmaceutical Co figured out a way around this problem. They designed a small molecule that can bind to the same receptor as GLP-1 and trigger it. It mimics the effect without mimicking the structure. 'It's a development I never would have thought feasible,' said Professor Michael Horowitz, a University of Adelaide researcher who authored a commentary on the drug in the Lancet. Chugai licensed the molecule to US-based Eli Lilly in 2018. Last week, the company reported participants on the highest dose in a clinical trial lost 7.9 per cent of their body weight over 40 weeks. The full details of the trial have not yet been reported, and whether the weight loss is maintained over the longer term is unclear. More than a quarter of patients reported diarrhoea, 16 per cent nausea and 14 per cent vomiting. The preliminary results are 'close enough to broadly call it similar' to semaglutide, said Professor Jonathan Shaw, who led the Australian arm of Lilly's trial at the Baker Heart and Diabetes Institute in Melbourne. 'I don't think we can confidently say it's better or worse. It's definitely in the same ballpark.' It's also not known if the drug will offer the range of other benefits that GLP-1 inhibitors provide in addition to weight loss, like reductions in cardiovascular disease and Alzheimer's risk (and maybe even addictive behaviours). Horowitz said the efficacy data was promising, but he wanted to see more information about adverse effects, which he said were understated generally across semaglutide trials because they relied on patients to report their own side effects. 'It hasn't served the interests of pharma to quantify how well this is tolerated.' Pfizer was developing a similar once-daily GLP-1 pill but cancelled the program in April after a patient in a clinical trial suffered liver damage. A pill should, theoretically, be cheaper and easier to make than an injector – Novo Nordisk, maker of Wegovy and its diabetes drug antecedent Ozempic, has struggled to keep up with demand for semaglutide – and dramatically easier to transport. At present, the drug must be kept refrigerated right from European factories to a patient's home. 'That all adds to the cost,' said Shaw. There could also be cost benefits from increased competition as more drugs are approved – possibly pushing the price down far enough for governments to consider subsidising it. Lilly expects to apply for regulatory approval for the drug later this year. While orforglipron has attracted the most excitement – Eli Lilly's shares have surged since they announced the trial results – it is just one of several new drugs in late-stage development. These drugs might be of particular value to 15 per cent or so of people whose bodies do not seem to respond to semaglutide. And people don't seem to stay on the injectable drugs – less than half are still using them a year later, per a study 2024 study – despite the fact weight rebound is likely if you stop using them. 'Is it the injection? Is it the cost? Or is it due to adverse effects? We don't know,' said Horowitz. The new drugs might also offer weight-loss benefits. Mounjaro, for example, mimics both GLP-1 and the gastric inhibitory polypeptide, which increases metabolism and appears to lead to better weight-loss results. The new drugs, like Lilly's retatrutide, target even more receptors, with the hope of even greater effects. It's all good news for Rochelle McDonald. She does not mind taking a weekly injection – 'the stabby-stab' – now she's found ways of coping with the side effects. But paying $240 a month for her current dose of the medicine is 'a commitment in itself'. 'I think a daily pill would be good,' she said. 'If it comes in at a good price point.'
7NEWS
4 days ago
- 7NEWS
Police appeal for help finding missing Victorian man Adam not seen for two months
There are concerns for a Victorian man who has been missing for two months after checking himself out of hospital. Adam, 38, was last seen walking on Bellarine St in Geelong at about 12.30am on April 27 after leaving Geelong University Hospital. Police say they have carried out 'extensive' searches across Geelong, Hoppers Crossing and Grovedale. Water Police also searched the Barwon River earlier this week but found nothing. 'Police and family have concerns for Adam's welfare due to the length of time he's been missing and his disappearance being out of character,' Victoria Police said. 'Adam has not used his phone, accessed his bank account or contacted any family members or friends since he went missing.' He does not have a car and will likely be on foot or using public transport. CCTV of Adam leaving the hospital and walking away has been released by police. In the footage, he was wearing a dark-green jumper, dark-grey tracksuit pants and black Nike shoes. He is described as being around 180cm tall, bald with a brown beard, and has a neck tattoo that says Jeremy Campbell. Anyone who sees Adam is urged to call Geelong Police Station.
